160 related articles for article (PubMed ID: 25149762)
41. Head and Neck Kaposi Sarcoma: Clinicopathological Analysis of 11 Cases.
Agaimy A; Mueller SK; Harrer T; Bauer S; Thompson LDR
Head Neck Pathol; 2018 Dec; 12(4):511-516. PubMed ID: 29508130
[TBL] [Abstract][Full Text] [Related]
42. The role of Kaposi sarcoma-associated herpesvirus in the pathogenesis of Kaposi sarcoma.
Gramolelli S; Schulz TF
J Pathol; 2015 Jan; 235(2):368-80. PubMed ID: 25212381
[TBL] [Abstract][Full Text] [Related]
43. Kaposi sarcoma.
Radu O; Pantanowitz L
Arch Pathol Lab Med; 2013 Feb; 137(2):289-94. PubMed ID: 23368874
[TBL] [Abstract][Full Text] [Related]
44. Human herpesvirus 8 in classic Kaposi sarcoma.
Kemény L; Kiss M; Gyulai R; Kenderessy AS; Adám E; Nagy F; Dobozy A
Acta Microbiol Immunol Hung; 1996; 43(4):391-5. PubMed ID: 9147730
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
46. Classic Kaposi sarcoma. Which KSHV-seropositive individuals are at risk?
Guttman-Yassky E; Dubnov J; Kra-Oz Z; Friedman-Birnbaum R; Silbermann M; Barchana M; Bergman R; Sarid R
Cancer; 2006 Jan; 106(2):413-9. PubMed ID: 16353205
[TBL] [Abstract][Full Text] [Related]
47. Differences in androgens of HIV positive patients with and without Kaposi sarcoma.
Christeff N; Winter C; Gharakhanian S; Thobie N; Wirbel E; Costagliola D; Nunez EA; Rozenbaum W
J Clin Pathol; 1995 Jun; 48(6):513-8. PubMed ID: 7665693
[TBL] [Abstract][Full Text] [Related]
48. Utility of immunohistochemical staining with FLI1, D2-40, CD31, and CD34 in the diagnosis of acquired immunodeficiency syndrome-related and non-acquired immunodeficiency syndrome-related Kaposi sarcoma.
Rosado FG; Itani DM; Coffin CM; Cates JM
Arch Pathol Lab Med; 2012 Mar; 136(3):301-4. PubMed ID: 22372906
[TBL] [Abstract][Full Text] [Related]
49. Mast Cell Activation and KSHV Infection in Kaposi Sarcoma.
Ayers LW; Barbachano-Guerrero A; McAllister SC; Ritchie JA; Asiago-Reddy E; Bartlett LC; Cesarman E; Wang D; Rochford R; Martin JN; King CA
Clin Cancer Res; 2018 Oct; 24(20):5085-5097. PubMed ID: 30084838
[No Abstract] [Full Text] [Related]
50. Positive staining of tumor-stage Kaposi sarcoma with lymphatic marker D2-40.
Dubina M; Goldenberg G
J Am Acad Dermatol; 2009 Aug; 61(2):276-80. PubMed ID: 19615538
[TBL] [Abstract][Full Text] [Related]
51. Elevation of soluble intercellular adhesion molecule-1 levels, but not angiopoietin 2, in the plasma of human immunodeficiency virus-infected African women with clinical Kaposi sarcoma.
Graham SM; Rajwans N; Richardson BA; Jaoko W; McClelland RS; Overbaugh J; Liles WC
Am J Trop Med Hyg; 2014 Oct; 91(4):705-8. PubMed ID: 25002294
[TBL] [Abstract][Full Text] [Related]
52. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant.
Vangipuram R; Tyring SK
Int J Dermatol; 2019 May; 58(5):538-542. PubMed ID: 29888407
[TBL] [Abstract][Full Text] [Related]
53. Oropharyngeal kaposi sarcoma in related persons negative for human immunodeficiency virus.
Sikora AG; Shnayder Y; Yee H; DeLacure MD
Ann Otol Rhinol Laryngol; 2008 Mar; 117(3):172-6. PubMed ID: 18444476
[TBL] [Abstract][Full Text] [Related]
54. Asymmetrical transmission of human herpesvirus 8 among spouses of patients with Kaposi sarcoma.
Dupuy A; Schulz T; Chevret S; Agbalika F; Pellet C; Janier M; Dupin N; Vérola O; Calvo F; Lebbé C
Br J Dermatol; 2009 Mar; 160(3):540-5. PubMed ID: 19077076
[TBL] [Abstract][Full Text] [Related]
55. Detection and titration of human herpesvirus-8-specific antibodies in sera from blood donors, acquired immunodeficiency syndrome patients, and Kaposi's sarcoma patients using a whole virus enzyme-linked immunosorbent assay.
Chatlynne LG; Lapps W; Handy M; Huang YQ; Masood R; Hamilton AS; Said JW; Koeffler HP; Kaplan MH; Friedman-Kien A; Gill PS; Whitman JE; Ablashi DV
Blood; 1998 Jul; 92(1):53-8. PubMed ID: 9639499
[TBL] [Abstract][Full Text] [Related]
56. A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma.
Séverin D; Bessaoud F; Meftah N; Du Thanh A; Tretarre B; Guillot B; Makinson A
AIDS; 2021 Mar; 35(3):399-405. PubMed ID: 33181532
[TBL] [Abstract][Full Text] [Related]
57. Kaposi sarcoma: no longer an AIDS-defining illness? A retrospective study of Kaposi sarcoma cases with CD4 counts above 300/mm³ at presentation.
Daly ML; Fogo A; McDonald C; Morris-Jones R
Clin Exp Dermatol; 2014 Jan; 39(1):7-12. PubMed ID: 23691969
[TBL] [Abstract][Full Text] [Related]
58. Bilateral tonsillar and esophageal Kaposi sarcoma in an HIV-negative patient.
Ozbudak IH; Guney K; Mutlu D; Gelen T; Ozbilim G
Ear Nose Throat J; 2011 Jul; 90(7):E23-6. PubMed ID: 21792787
[TBL] [Abstract][Full Text] [Related]
59. Disseminated vitiligo developing around Kaposi sarcoma nodules in an AIDS patient.
Elsaie ML; Shehu YM; Sani MU; Borodo MM; Mohammed AZ
Cutis; 2011 Nov; 88(5):237-9. PubMed ID: 22272487
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of a Predictive Staging Model for HIV-Associated Kaposi Sarcoma in Uganda.
Okuku F; Krantz EM; Kafeero J; Kamya MR; Orem J; Casper C; Phipps W
J Acquir Immune Defic Syndr; 2017 Apr; 74(5):548-554. PubMed ID: 28107226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
